TP219 inhibits virus morphogenesis.

<p>(<b>A</b>) Structural formula of TP219. (<b>B</b>) Effect of TP219 on cell viability and CVB3-induced cytopathic effect in BGM cells. Toxicity (black circles) and CPE (white squares) was quantified by MTS assay at 3 d p.i. and expressed as percentage of untreated controls. Data are average values ± SD. (<b>C</b>) Analysis of the effect of TP219 on RNA replication and infectious virus titers. BGM cells were infected with RLuc-CVB3. The indicated compounds were added immediately after infection at the indicated concentrations. The enterovirus inhibitors GuaHCl and geldanamycin were included as controls. At 8 h p.i. intracellular viral RNA replication in the absence or presence of the indicated molecules was quantified by measuring luciferase activity (<b>C, left panel</b>). Lysates were used to determine infectious virus yields calculated by endpoint titration and expressed as the tissue culture 50% infectious dose per ml (TCID₅₀) (<b>C, right panel</b>). Experiments were performed in triplicate and mean values ± SD are depicted. (<b>D</b>) Effect of TP219 on polyprotein processing. Cells were infected with CVB3 at MOI 50 and pulse-labeled with Methionine ^3S[S] in the absence or presence of TP219. Subsequently, proteins were analyzed by SDS-PAGE.